Fulcrum Therapeutics (FULC) News Today $4.35 +0.32 (+7.94%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Fulcrum Therapeutics (NASDAQ:FULC) shareholders have endured a 77% loss from investing in the stock three years agoDecember 19 at 1:04 PM | finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $9.33 Average Target Price from BrokeragesDecember 18 at 1:32 AM | americanbankingnews.comCharles Schwab Investment Management Inc. Has $2.03 Million Holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Charles Schwab Investment Management Inc. boosted its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 223.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 569,185 sharesDecember 17, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Hold" by AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been given a consensus recommendation of "Hold" by the ten research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a holdDecember 15, 2024 | marketbeat.comFulcrum sketching out future plans for Bridge District in West SacramentoDecember 13, 2024 | bizjournals.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Fmr LLCFmr LLC lessened its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 67.7% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,724,015 shares of the company's stock after selling 3,605,931 shDecember 13, 2024 | marketbeat.com202,030 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Purchased by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 202,030 shares of the company's stock, valued at approximately $721,000. Jacobs Levy EqDecember 10, 2024 | marketbeat.com20 Reasons Why Employees And Leaders Make Time For One-On-One MeetingsDecember 5, 2024 | forbes.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Position Reduced by RA Capital Management L.P.RA Capital Management L.P. trimmed its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 11.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,229,099 shares of the company's stock after seDecember 5, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Acquires Shares of 132,784 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Connor Clark & Lunn Investment Management Ltd. bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 132,784 shares of the companyNovember 30, 2024 | marketbeat.comBraidwell LP Purchases New Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Braidwell LP acquired a new position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,069,158 shares of the company's stockNovember 29, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Sold by Suvretta Capital Management LLCSuvretta Capital Management LLC decreased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 53.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,182,791 shares of the company's stock after selling 1,358,255 shareNovember 29, 2024 | marketbeat.comFulcrum Therapeutics (FULC) Upgraded to Buy: Here's WhyNovember 28, 2024 | msn.comFulcrum Therapeutics to Participate in Upcoming December ConferencesNovember 26, 2024 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received an average rating of "Hold" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and threeNovember 20, 2024 | marketbeat.comResearch Analysts Issue Forecasts for FULC FY2024 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at HC Wainwright raised their FY2024 EPS estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will postNovember 18, 2024 | marketbeat.comSimplify Asset Management Inc. Sells 323,518 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Simplify Asset Management Inc. reduced its position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 47.9% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 351,314 shares of the company's stock after selling 323,518 sharesNovember 15, 2024 | marketbeat.comCautious Hold Rating on Fulcrum Therapeutics Amid Uncertain Prospects and Strategic ShiftsNovember 15, 2024 | markets.businessinsider.comFulcrum Therapeutics Third Quarter 2024 Earnings: US$0.35 loss per share (vs US$0.39 loss in 3Q 2023)November 15, 2024 | finance.yahoo.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | msn.comFulcrum Therapeutics' (FULC) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reiterated a "neutral" rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday.November 14, 2024 | marketbeat.comFulcrum Therapeutics expects cash to fund operations into at least 2027November 14, 2024 | markets.businessinsider.comFulcrum Therapeutics Reports Q3 2024 Financial ProgressNovember 14, 2024 | markets.businessinsider.comFulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | seekingalpha.comFulcrum Therapeutics to Participate in the Stifel Healthcare ConferenceNovember 12, 2024 | globenewswire.comFulcrum Therapeutics (FULC) Scheduled to Post Earnings on WednesdayFulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Wednesday, November 13, Zacks reports.November 7, 2024 | marketbeat.comFulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ETNovember 6, 2024 | globenewswire.comAssenagon Asset Management S.A. Has $1.22 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Assenagon Asset Management S.A. reduced its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 31.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 340,495 shares of the company's stockNovember 2, 2024 | marketbeat.comShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Decreases By 6.4%Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large decline in short interest in October. As of October 15th, there was short interest totalling 5,520,000 shares, a decline of 6.4% from the September 30th total of 5,900,000 shares. Based on an average daily volume of 1,650,000 shares, the days-to-cover ratio is currently 3.3 days.October 31, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have received a consensus recommendation of "Hold" from the ten brokerages that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have assigned a hold ratiOctober 26, 2024 | marketbeat.comWe're Interested To See How Fulcrum Therapeutics (NASDAQ:FULC) Uses Its Cash Hoard To GrowOctober 21, 2024 | finance.yahoo.comAvidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats UpOctober 18, 2024 | msn.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 11, 2024 | globenewswire.comFulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...October 9, 2024 | finance.yahoo.comFulcrum Therapeutics Sees Unusually High Options Volume (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw unusually large options trading on Wednesday. Stock investors purchased 30,075 call options on the company. This represents an increase of approximately 1,522% compared to the typical volume of 1,854 call options.October 9, 2024 | marketbeat.comDimensional Fund Advisors LP Has $9.18 Million Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Dimensional Fund Advisors LP increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 13.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,480,926 shares of the company's stock aftOctober 8, 2024 | marketbeat.comFMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc SharesOctober 7, 2024 | gurufocus.comPetri Dish: IPO-bound drugmaker strikes BioMarin deal, plus other biotech newsOctober 3, 2024 | bizjournals.comHealthy Returns: Pfizer pulls sickle cell disease drug from markets – here’s why it mattersOctober 1, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Growth in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 11,400,000 shares, a growth of 41.4% from the August 31st total of 8,060,000 shares. Based on an average trading volume of 1,680,000 shares, the days-to-cover ratio is presently 6.8 days.September 29, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock, Insider Trading ActivitySeptember 27, 2024 | benzinga.comFulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market OpportunitySeptember 27, 2024 | marketwatch.comFulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setbackSeptember 27, 2024 | msn.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 25, 2024 | globenewswire.comFulcrum Therapeutics to Cut 29 Jobs Amid Reprioritization of R&DSeptember 24, 2024 | marketwatch.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 23, 2024 | prnewswire.com186,727 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by Bank of New York Mellon CorpBank of New York Mellon Corp bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 186,727 shares of the compaSeptember 21, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 19, 2024 | globenewswire.comBrokers Issue Forecasts for Fulcrum Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Stock analysts at Leerink Partnrs lifted their FY2024 earnings estimates for Fulcrum Therapeutics in a research report issued to clients and investors on Thursday, September 12th. Leerink Partnrs analyst J. Schwartz now anticipates that theSeptember 16, 2024 | marketbeat.comFULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 15, 2024 | prnewswire.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼0.620.60▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼44▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BCAX News Today ZYME News Today GYRE News Today PSTX News Today PAHC News Today COGT News Today NUVB News Today AVBP News Today IMTX News Today QURE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
